Browsing Harvard Medical School by Author "Cannon, Christopher"
Now showing items 1-11 of 11
-
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
Cannon, Christopher P.; Gropper, Savion; Bhatt, Deepak L.; Ellis, Stephen G.; Kimura, Takeshi; Lip, Gregory Y.H.; Steg, Ph. Gabriel; ten Berg, Jurriën M.; Manassie, Jenny; Kreuzer, Jörg; Blatchford, Jon; Massaro, Joseph M.; Brueckmann, Martina; Ferreiros Ripoll, Ernesto; Oldgren, Jonas; Hohnloser, Stefan H. (Wiley Periodicals, Inc., 2016)Antithrombotic management of patients with atrial fibrillation (AF) undergoing coronary stenting is complicated by the need for anticoagulant therapy for stroke prevention and dual antiplatelet therapy for prevention of ... -
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Cannon, Christopher P.; Cariou, Bertrand; Blom, Dirk; McKenney, James M.; Lorenzato, Christelle; Pordy, Robert; Chaudhari, Umesh; Colhoun, Helen M. (Oxford University Press, 2015)Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, compared with ezetimibe, as add-on ... -
Elevated White Cell Count in Acute Coronary Syndromes: Relationship to Variants in Inflammatory and Thrombotic Genes
Byrne, Connie E.; Fitzgerald, Desmond J.; Shields, Denis C.; Fitzgerald, Anthony; Cannon, Christopher Paul (BioMed Central, 2004)Background: Elevated white blood cell counts (WBC) in acute coronary syndromes (ACS) increase the risk of recurrent events, but it is not known if this is exacerbated by pro-inflammatory factors. We sought to identify ... -
Genetic Risk, Coronary Heart Disease Events, and the Clinical Benefit of Statin Therapy: An Analysis of Primary and Secondary Prevention Trials
Mega, Jessica L.; Stitziel, Nathan O.; Smith, J. Gustav; Chasman, Daniel; Caulfield, Mark; Devlin, James J.; Nordio, Francesco; Hyde, Craig L.; Cannon, Christopher; Sacks, Frank; Poulter, Neil; Sever, Peter S.; Ridker, Paul; Braunwald, Eugene; Melander, Olle; Kathiresan, Sekar; Sabatine, Marc (Elsevier BV, 2015-06-06)Background Genetic variants have been associated with the risk of coronary heart disease (CHD). We tested whether a composite of these variants could identify the risk of both incident as well as recurrent CHD events and ... -
Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease
O, Michelle L.; Morrow, David Andrew; Tsimikas, Sotirios; Sloan, Sarah; Ren, Angela F.; Hoffman, Elaine; Desai, Nihar R.; Solomon, Scott David; Domanski, Michael; Arai, Kiyohito; Chiuve, Stephanie Elizabeth; Cannon, Christopher Paul; Sacks, Frank Martin; Sabatine, Marc Steven (Elsevier BV, 2014)OBJECTIVES: The purpose of this study was to assess the prognostic utility of lipoprotein(a) [Lp(a)] in individuals with coronary artery disease (CAD). BACKGROUND: Data regarding an association between Lp(a) and ... -
Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
Wallentin, Lars; Held, Claes; Armstrong, Paul W.; Cannon, Christopher P.; Davies, Richard Y.; Granger, Christopher B.; Hagström, Emil; Harrington, Robert A.; Hochman, Judith S.; Koenig, Wolfgang; Krug‐Gourley, Sue; Mohler, Emile R.; Siegbahn, Agneta; Tarka, Elizabeth; Steg, Philippe Gabriel; Stewart, Ralph A. H.; Weiss, Robert; Östlund, Ollie; White, Harvey D.; Budaj, Andrzej; Ardissino, Diego; Avezum, Alvaro; Aylward, Philip E.; Bryce, Alfonso; Chen, Hong; Chen, Ming‐Fong; Corbalan, Ramon; Dalby, Anthony J.; Danchin, Nicolas; De Winter, Robbert J.; Denchev, Stefan; Diaz, Rafael; Elisaf, Moses; Flather, Marcus D.; Goudev, Assen R.; Grinfeld, Liliana; Husted, Steen; Kim, Hyo‐Soo; Linhart, Ales; Lonn, Eva; López‐Sendón, José; Manolis, Athanasios J.; Nicolau, José C.; Pais, Prem; Parkhomenko, Alexander; Pedersen, Terje R.; Pella, Daniel; Ramos‐Corrales, Marco A.; Ruda, Mikhail; Sereg, Mátyás; Siddique, Saulat; Sinnaeve, Peter; Sritara, Piyamitr; Swart, Henk P.; Sy, Rody G.; Teramoto, Tamio; Tse, Hung‐Fat; Weaver, W. Douglas; Viigimaa, Margus; Vinereanu, Dragos; Zhu, Junren (John Wiley and Sons Inc., 2016)Background: We evaluated lipoprotein‐associated phospholipase A2 (Lp‐PLA 2) activity in patients with stable coronary heart disease before and during treatment with darapladib, a selective Lp‐PLA 2 inhibitor, in relation ... -
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Morrow, David Andrew; Wang, Yunmei; Croce, Kevin James; Sakuma, Masashi; Sabatine, Marc Steven; Gao, Huiyun; Pradhan, Aruna Das; Healy, Aileen M.; Buros, Jacki; McCabe, Carolyn; Libby, Peter; Cannon, Christopher Paul; Braunwald, Eugene; Simon, Daniel I. (Elsevier BV, 2008)Background Using a transcriptional profiling approach, we recently identified myeloid-related protein 8/14 (MRP-8/14) to be expressed by platelets during acute myocardial infarction (MI). Elevated concentrations of MRP-8/14 ... -
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control
Ray, Kausik K.; Ginsberg, Henry N.; Davidson, Michael H.; Pordy, Robert; Bessac, Laurence; Minini, Pascal; Eckel, Robert H.; Cannon, Christopher P. (Lippincott Williams & Wilkins, 2016)Background: A continuous relationship between reductions in low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) has been observed in statin and ezetimibe outcomes trials down to ... -
Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
Rey, Jacques; Poitiers, Franck; Paehler, Tobias; Brunet, Aurélie; DiCioccio, A. Thomas; Cannon, Christopher P.; Surks, Howard K.; Pinquier, Jean‐Louis; Hanotin, Corinne; Sasiela, William J. (John Wiley and Sons Inc., 2016)Background: Alirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear. ... -
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Andell, Pontus; James, Stefan K.; Cannon, Christopher P.; Cyr, Derek D.; Himmelmann, Anders; Husted, Steen; Keltai, Matyas; Koul, Sasha; Santoso, Anwar; Steg, Ph. Gabriel; Storey, Robert F.; Wallentin, Lars; Erlinge, David (John Wiley and Sons Inc., 2015)Background: Patients with chronic obstructive pulmonary disease (COPD) experiencing acute coronary syndromes (ACS) are at high risk for clinical events. In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ... -
Trends in Clinical, Demographic, and Biochemical Characteristics of Patients with Acute Myocardial Infarction from 2003 to 2008: A Report from the American Heart Association Get with the Guidelines Coronary Artery Disease Program
Boyer, Nathan M.; Laskey, Warren K.; Cox, Margueritte; Hernandez, Adrian F.; Peterson, Eric D.; Bhatt, Deepak L.; Cannon, Christopher Paul; Fonarow, Gregg C. (Blackwell Publishing Ltd, 2012)Background: An analysis of the changes in the clinical and demographic characteristics of patients with acute myocardial infarction could identify successes and failures of risk factor identification and treatment of ...